NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 189)
Posted On: 02/26/2019 4:27:42 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Supports Recent FDA Statement on Novel Nicotine Replacement Therapies
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning conveyed its support for the Food & Drug Administration’s (“FDA”) February 21 statement titled “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products”. The FDA’s statement outlined the development of safe and effective novel nicotine replacement therapies to help smokers quit cigarettes, stating that “novel products with different characteristics or routes of nicotine delivery have the potential to offer additional opportunities for health-concerned smokers interested in quitting.” Lexaria recently entered a partnership with a leading tobacco company to use DehydraTECH(TM) technology to develop new oral nicotine products. This technology could provide a nicotine delivery method that harmonizes with current FDA policies while avoiding the grave health consequences related to smoking cigarettes and preserving the consumers’ choice.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning conveyed its support for the Food & Drug Administration’s (“FDA”) February 21 statement titled “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products”. The FDA’s statement outlined the development of safe and effective novel nicotine replacement therapies to help smokers quit cigarettes, stating that “novel products with different characteristics or routes of nicotine delivery have the potential to offer additional opportunities for health-concerned smokers interested in quitting.” Lexaria recently entered a partnership with a leading tobacco company to use DehydraTECH(TM) technology to develop new oral nicotine products. This technology could provide a nicotine delivery method that harmonizes with current FDA policies while avoiding the grave health consequences related to smoking cigarettes and preserving the consumers’ choice.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼